NDANASALSPRAY
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
REZENOPY (naloxone hcl) by Hikma is sites. Approved for opioid overdose. First approved in 2024.
Drug data last refreshed 19h ago
Mechanism of Action
sites. Administration of naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation and hypotension. It can also reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.
Indications (1)
Company
Worked on REZENOPY at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.